Find the buyers most likely to be in.
Set a target profile and get the strategic and financial buyers most likely to be relevant, ranked from verified European deal history. Deterministic scoring with published weights, defensible in a kickoff meeting. How the score works
Start from a company
Type any company, covered or not. We read its public footprint and pre-fill the profile.
Company name or website · covered or not, we pre-fill sector and country from its public footprint
Or build the profile yourself
Sector
The target's industry family
Sub-sector
Optional precision within the family
Country
Where the company operates from · 16 European markets
Target size (EV)
Optional · adds a check-size fit against each fund
Sector match
Strict keeps only buyers with in-sector deals · Broad admits neighbouring sectors
Geography match
Strict requires deals in the country itself · Broad counts the rest of Europe
Target: Aurobac Therapeutics · Biotech · France · scored as Biotech · France, edit the profile above
How companies like this sold · 392 verified exits: 35% to sponsors, 60% to corporates and platforms, 4% via IPO, 1% other routes.
Route shift since 2020: sponsors 31% (was 42%), corporates and platforms 65% (was 50%), IPO 2% (was 8%).
Recent deals in this marketAlantra Private Equity Healthcare Continuation Fund closed Deudafix (2026) · Amethis closed ADEMAT (2026) · Apheon closed Alma (2026) · Apheon TMC HDC Long Term Value Fund (HarbourVest-led) + LFPI closed Alma (2026) · Apheon TMC HDC Long Term Value Fund SCSp (HarbourVest + LFPI-backed continuation fund) closed Alma (2026)
10 of the top 10 closed a deal in this space in the last 12 months.
Likely buyers · Biotech in France.
Memo view · print-readyRanked by fit on sector, geography, recency, current exposure and timing. Strength labels and tiers are published thresholds, not editorial picks.
Financial buyers 10
| # | Buyer | Match | ||||
|---|---|---|---|---|---|---|
| Tier 1 · Very High · score 70+ | ||||||
| 1 | Bpifrance Investissement | 90Very High | ||||
| 2 | ArchiMed | 86Very High | ||||
| 3 | Archimedes Partners | 86Very High | ||||
| 4 | ARCHIMED and Institut Mérieux | 86Very High | ||||
| 5 | ArchiMed and Tethys Invest | 86Very High | ||||
| 6 | Turenne Groupe | 84Very High | ||||
| 7 | Audacia | 84Very High | ||||
| 8 | Ring Capital | 84Very High | ||||
| 9 | Merieux Equity Partners / Vitruvian Partners | 83Very High | ||||
| 10 | Irdi Capital-Investissement | 82Very High | ||||
The full shortlist is open, precedents included. Pro adds the working tools.
Export the tiered buyer list to Excel, precedents and timing in the cells · Sourced press links on census add-on deals · Custom scoring weights